Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAM | P19021 | 1/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.44 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.44 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.44 |
| ▸ | PDE5A | O76074 | 2/20 | 0.43 |
| ▸ | SMPD2 | O60906 | 2/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.35 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18555680 | 0.86 | PTGER1 (0.41) | PTGER1PTGER4PTGER3PTGER2PDE5A | |
| SCHEMBL18555678 | 0.86 | PTGER1 (0.41) | PTGER1PTGER4PTGER3PTGER2PDE5A | |
| SCHEMBL18555186 | 0.84 | KMT2A (0.43) | PTGER1PTGER4PTGER3PTGER2PDE5A | |
| SCHEMBL18555187 | 0.84 | KMT2A (0.43) | PTGER1PTGER4PTGER3PTGER2PDE5A | |
| SCHEMBL14966877 | 0.83 | PAM (0.50) | PAMPTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL14966874 | 0.83 | PAM (0.50) | PAMPTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL18555490 | 0.80 | PTGER3 (0.52) | PTGER1PTGER4PTGER3PTGER2KDM4E | |
| SCHEMBL18555493 | 0.80 | PTGER3 (0.52) | PTGER1PTGER4PTGER3PTGER2KDM4E | |
| SCHEMBL17341956 | 0.76 | PTGER4 (0.43) | PTGER1PTGER4PTGER3PTGER2KDM4E | |
| SCHEMBL8844798 | 0.75 | SMPD2 (0.58) | PAMSMPD2GRIK1GRIK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377716-B2 | Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180029990-A1 | COMPOSITION AND METHOD FOR PREVENTION, MITIGATION OR TREATMENT OF AN ENTEROPATHOGENIC BACTERIAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-01 | — | — | US | disclosed |
| US-9790186-B2 | Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790186-B2 | Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2017-10-17 | — | — | US | disclosed |
| US-20150361045-A1 | COMPOSITION AND METHOD FOR PREVENTION, MITIGATION OR TREATMENT OF AN ENTEROPATHOGENIC BACTERIAL INFECTION | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377716-B2 | Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection | FABP2, LRBA, VIP | PAM 906/4885PTGER1 353/4885PTGER4 722/4885 |
| US-20150361045-A1 | COMPOSITION AND METHOD FOR PREVENTION, MITIGATION OR TREATMENT OF AN ENTEROPATHOGENIC BACTERIAL INFECTION | FABP2, LRBA, VIP | PAM 906/4885PTGER1 353/4885PTGER4 722/4885 |
| US-20180029990-A1 | COMPOSITION AND METHOD FOR PREVENTION, MITIGATION OR TREATMENT OF AN ENTEROPATHOGENIC BACTERIAL INFECTION | FABP2, LRBA, VIP | PAM 906/4885PTGER1 353/4885PTGER4 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.